Abstract
Long-lasting numbness of soft tissues such as lips, tongue, and cheeks after dental anesthesia is not only unpleasant but has the potential to cause self-inflicted damage to the numb tissue. Phentolamine mesylate, when injected in vicinity to the site of local anesthesia, accelerates the absorption of local anesthesia. Dental use of this drug was approved in the United States and Canada in 2008 and 2014, respectively. The rapidly increasing popularity of this novel technology (intraoral phentolamine injections) warrants a health technology assessment for clinicians. A medical librarian conducted a systematic literature search (up to March 1, 2016) for any clinical study involving intraoral phentolamine injection. Meta-analysis of the efficacy data from 4 clinical studies supports the role of intraoral phentolamine injections in shortening the duration of numbness after local anesthesia. No publication bias was found in the selected studies. The selected studies identified no serious adverse events other than pain at the site of injection and some postprocedural pain. Our cost-effectiveness analysis shows phentolamine mesylate to be an effective treatment modality when compared with no treatment, sham, or placebo injection. Phentolamine mesylate incurs an additional cost (in US dollars) of $0.13 to $0.16 per minute of reversing the soft tissue local anesthesia and $0.38 to $0.46, when compared with sham or placebo injection, after a noninvasive dental procedure. The literature lacked substantial evidence in favor of clinical benefits, such as a decrease in self-inflicted injuries. Only a subgroup of the dental patient population undergoing specific dental procedures would benefit from accelerated recovery from numbness.
Keywords
Get full access to this article
View all access options for this article.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
